Lytic therapy in central venous catheters for hemodialysis.
Over the past 2 decades the use of central venous catheters (CVCs) for hemodialysis has become commonplace. While these devices have provided much needed temporary access to the bloodstream, they often become thrombosed and require procedures to restore patency. This article examines the lytic enzymes that are currently available and focuses on the assessment and treatment of thrombosis.
McFarland
Holly Fadness
HF
Nephrology Department, UNC School of Medicine in Chapel Hill, NC, USA.
Dinwiddie
Lesley
L
Ferrell
Janice
J
Forloines-Lynn
Sue
S
D002405:Catheterization, Central Venous / Q000009:adverse effects* / Q000451:nursing; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D006801:Humans; D011994:Recombinant Proteins / Q000008:administration & dosage; D006435:Renal Dialysis / Q000009:adverse effects*; D013300:Streptokinase / Q000008:administration & dosage; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control / Q000628:therapy*; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage
D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; C087896:reteplase; D013300:Streptokinase; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator